EFS for real-world patients with R/R PTCL and CTCL receiving combination duv/romi. Kaplan-Meier curves show EFS estimates since duv/romi treatment initiation. (A) Overall cohort with standard censoring. (B) Overall cohort with allo-HSCT after duv/romi as censoring events. (C) Comparison by histological subtype (nTFH vs non-nTFH) with standard censoring. (D) Comparison by histological subtype (nTFH vs non-nTFH) and allo-HSCT censored. (E) Comparison by histological subtype (PTCL-NOS, nTFH subtype, and other) with standard censoring. (F) Comparison by histological subtype (PTCL-NOS, nTFH subtype, and other) and allo-HSCT censored. P values calculated by log-rank test. EFS, event-free survival.